Vítejte v kongresovém kalendáři, který je určený pro odbornou veřejnost. Najdete zde pozvánky na kongresy a konference, semináře i webináře a také vzdělávací kurzy. Od srpna 2024 jsme do kalendáře zařadili také akce, které se pořádají pro laickou veřejnost. Pomůckou pro rychlou orientaci je Vám barevné rozlišení: tuzemské ace pro odborníky jsou vyznačeny červeně, zahraniční akce pro odborníky tmavě modrou a akce pořádané pro onkologické pacienty, jejich rodiny a laiky světle modrou.
-
Přidat do kalendáře:
2009-10-20 00:00:00
2009-10-23 23:59:59
Europe/Prague
Medical Fair Brno 2009
Výstaviště Brno, Brno
Výstaviště Brno, Brno
The Westin Michigan Avenue Chicago, Chicago, Illinois, USA
-
Přidat do kalendáře:
2009-10-21 00:00:00
2009-10-22 23:59:59
Europe/Prague
Bronchogenní karcinom
Hotel ILF, Praha
Hotel ILF, Praha
EuroAgentur Business Hotel Jihlava, Jihlava
Seminář je součástí projektu „Zastavme kolorektální karcinom“,
jehož cílem je informovat odbornou veřejnost o Národním programu
screeningu a o potřebě a možnostech včasné diagnostiky
kolorektálního karcinomu v České republice.
přednáškový sál, 4. p., Švejdův pavilon, MOÚ Brno, Brno
Výstaviště Brno, pavilon A3 - Rotunda, Brno
POŘADATEL
Česká lékařská společnost J. E.
Purkyně ve spolupráci s Českou onkologickou společností ČLS JEP
Odbornou společností praktických dětských lékařů ČLS JEP
Společností všeobecného lékařství ČLS JEP a Slovenskou lekárskou
spoločnosťou
PREZIDENTI KONGRESU
Prof. MUDr. Jaroslav Blahoš, DrSc. -
předseda České lékařské společnosti J. E. Purkyně
Prof. MUDr. Peter Krištúfek, CSc. - prezident Slovenskej lekárskej spoločnosti
Prof. MUDr. Peter Krištúfek, CSc. - prezident Slovenskej lekárskej spoločnosti
ODBORNÁ GARANCE
Prof. MUDr. Jiří Vorlíček, CSc. -
předseda ČOS ČLS JEP
Doc. MUDr. Svatopluk Býma, CSc. - předseda SVL ČLS JEP
MUDr. Hana Cabrnochová - předsedkyně OSPDL ČLS JEP
Doc. MUDr. Svatopluk Býma, CSc. - předseda SVL ČLS JEP
MUDr. Hana Cabrnochová - předsedkyně OSPDL ČLS JEP
-
Přidat do kalendáře:
2009-10-22 00:00:00
2009-10-23 23:59:59
Europe/Prague
IDIBELL Cancer Conference on Sirtuins 2009
Bellvitge Institute for Biomedical Research, Barcelona, Spain
Bellvitge Institute for Biomedical Research, Barcelona, Spain
-
Přidat do kalendáře:
2009-10-22 00:00:00
2009-10-24 23:59:59
Europe/Prague
XVI. Jihočeské onkologické dny
Český Krumlov
Český Krumlov
Brno
Konference je určena lékařům a sestrám všech oborů, kteří ve své
praxi přicházejí do styku s nevyléčitelně nemocnými a umírajícími
pacienty.
-
Přidat do kalendáře:
2009-10-22 00:00:00
2009-10-23 23:59:59
Europe/Prague
5th EBMT Lymphoma Working Party Educational Course Haematopoietic Stem Cell Transplantation and Lymphoma
Engineers' House, Clifton Down,, Bristol, UK
Engineers' House, Clifton Down,, Bristol, UK
Karolinum, Celetná 20, Praha 1
Pořadatelé: ČHS ČLS JEP
-
Přidat do kalendáře:
2009-10-22 00:00:00
2009-10-24 23:59:59
Europe/Prague
Lymphoma and Myeloma 2009: An International Congress on Hematologic Malignancies
Témata:
Biology of CLL
New insights into CLL biology
CLL genomics and epigenetics
How do we make sense of prognostic markers?
Treatment of CLL
Standard treatment of CLL: Evidencebased approaches to
untreated and previously treated patients
Evidence-based approaches for relapsed treatment
Latest results with IMiDS compounds in CLL: How do we manage
the rash/flare and what does it mean?
Experimental and recently approved novel agents in CLL
Lymphoplasmocytic disorders
Waldenstrom’s macroglobulinemia: An update
POEMS and Castleman’s disease: Is there a role for novel
agents?
Amyloidosis: Recent data
Biology of lymphoma
The biologic and pathologic basis for the new WHO
classification
A clinician’s view of the new
WHO classification
John Ultmann Award Lecture: Hodgkin’s disease: The past, the
present and the future
T cell lymphoma
What is the best front line strategy for peripheral T-cell
lymphoma: Is there a role of novel agents and transplantation?
Have we made progress in the systemic therapy of treating
cutaneous T-cell lymphoma?
Angioimmunoblastic lymphadenopathy: What is latest in biology
and treatment
Mantle cell lymphoma
Debate: Should mantle cell be treated aggressively from the
onset?
Special concerns in large cell lymphoma
Biology and treatment of bulky and mediastinal large cell
disease: Is EPOCH really better than CHOP-R with/without
radiation?
How to prevent and treatment central nervous system
disease
How can we improve on large cell lymphoma treatment?
Genomic/epigenetic targeting of large cell lymphoma: Does it
have clinical application?
Low grade lymphoma
Is follicular lymphoma curable? If not, has it become a chronic
illness?
Strategies for low grade lymphoma: How to use prognostic
indicators in treatment
Lymphomas of the eye: MALT, follicular, large cell
Novel agents in low grade lymphoma: More than we can
handle?
Vaccines redux: Useless or a phoenix?
Hodgkin’s disease: PET scanning
Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s
lymphoma
The new promise of PET scans
The new peril of PET scans
Biology of myeloma
Chromosomes, genomics and proteomics as a disease primer
Myeloma cell trafficking and mobilization
Debate: Does the myeloma stem cell exist? Can we target it for
therapeutic purposes?
Targeting the cell cycle in myeloma and lymphoma
Clinical pathology and myeloma
Measurement of free light and heavy chains: Applications?
Minimal residual disease in myeloma: Flow cytometry and
molecular techniques
The Tower of Babel: Multiple response criteria and the need for
a unified standard: Summary of the IMW consensus on response
criteria and relevant outcomes
Special lecture: Targeted therapy in myeloma
Joseph Michaeli Award Lecture: Kinetics, proliferation and
novel agents in myeloma: Is autologous transplantaion old hat?
Clinical cases and debates in myeloma
First Line Therapy: Poor risk patient
Debate: Sequential vs. combination therapy, triplets or
more
Consolidaton: Good risk patient
Debate: Transplant vs. no transplant
First Line Therapy: Non transplant candidate
Debate: Bortezomib based vs. IMiD based
Relapse and refractory disease
Novel combination therapies for the treatment of
relapsed/refractory multiple myeloma: Current phase I/II,
combinations using as backbone IMiDs and proteasome inhibitors
Special lecture
Highlights from the 2009 International Myeloma Workshop: Are we
nearing a cure in myeloma?
Waldorf=Astoria, New York, USA
Waldorf=Astoria, New York, USA
Témata:
Biology of CLL
- New insights into CLL biology
- CLL genomics and epigenetics
- How do we make sense of prognostic markers?
Treatment of CLL
- Standard treatment of CLL: Evidencebased approaches to untreated and previously treated patients
- Evidence-based approaches for relapsed treatment
- Latest results with IMiDS compounds in CLL: How do we manage the rash/flare and what does it mean?
- Experimental and recently approved novel agents in CLL
Lymphoplasmocytic disorders
- Waldenstrom’s macroglobulinemia: An update
- POEMS and Castleman’s disease: Is there a role for novel agents?
- Amyloidosis: Recent data
Biology of lymphoma
- The biologic and pathologic basis for the new WHO classification
- A clinician’s view of the new
WHO classification
- John Ultmann Award Lecture: Hodgkin’s disease: The past, the present and the future
T cell lymphoma
- What is the best front line strategy for peripheral T-cell lymphoma: Is there a role of novel agents and transplantation?
- Have we made progress in the systemic therapy of treating cutaneous T-cell lymphoma?
- Angioimmunoblastic lymphadenopathy: What is latest in biology and treatment
Mantle cell lymphoma
- Debate: Should mantle cell be treated aggressively from the onset?
Special concerns in large cell lymphoma
- Biology and treatment of bulky and mediastinal large cell disease: Is EPOCH really better than CHOP-R with/without radiation?
- How to prevent and treatment central nervous system disease
- How can we improve on large cell lymphoma treatment?
- Genomic/epigenetic targeting of large cell lymphoma: Does it have clinical application?
Low grade lymphoma
- Is follicular lymphoma curable? If not, has it become a chronic illness?
- Strategies for low grade lymphoma: How to use prognostic indicators in treatment
- Lymphomas of the eye: MALT, follicular, large cell
- Novel agents in low grade lymphoma: More than we can handle?
- Vaccines redux: Useless or a phoenix?
Hodgkin’s disease: PET scanning
- Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s lymphoma
- The new promise of PET scans
- The new peril of PET scans
Biology of myeloma
- Chromosomes, genomics and proteomics as a disease primer
- Myeloma cell trafficking and mobilization
- Debate: Does the myeloma stem cell exist? Can we target it for therapeutic purposes?
- Targeting the cell cycle in myeloma and lymphoma
Clinical pathology and myeloma
- Measurement of free light and heavy chains: Applications?
- Minimal residual disease in myeloma: Flow cytometry and molecular techniques
- The Tower of Babel: Multiple response criteria and the need for a unified standard: Summary of the IMW consensus on response criteria and relevant outcomes
- Special lecture: Targeted therapy in myeloma
- Joseph Michaeli Award Lecture: Kinetics, proliferation and novel agents in myeloma: Is autologous transplantaion old hat?
Clinical cases and debates in myeloma
- First Line Therapy: Poor risk patient
- Debate: Sequential vs. combination therapy, triplets or more
- Consolidaton: Good risk patient
Debate: Transplant vs. no transplant
- First Line Therapy: Non transplant candidate
- Debate: Bortezomib based vs. IMiD based
Relapse and refractory disease
- Novel combination therapies for the treatment of relapsed/refractory multiple myeloma: Current phase I/II, combinations using as backbone IMiDs and proteasome inhibitors
Special lecture
- Highlights from the 2009 International Myeloma Workshop: Are we nearing a cure in myeloma?
-
Přidat do kalendáře:
2009-10-22 00:00:00
2009-10-25 23:59:59
Europe/Prague
ESH Conference MYELODYSPLASTIC SYNDROMES
Pullman Mandelieu Royal Casino hotel, Mandelieu, Francie
Pullman Mandelieu Royal Casino hotel, Mandelieu, Francie
Milan, Italy
-
Přidat do kalendáře:
2009-10-23 00:00:00
2009-10-25 23:59:59
Europe/Prague
Genová a buněčná terapie a imunoterapie nádorů 2009
Zámek Liblice Konferenční centrum, Byšice
Zámek Liblice Konferenční centrum, Byšice
